Relapsed Refractory Multiple Myeloma (RRMM) Latest Advances

Find the Latest Research About Relapsed Refractory Multiple Myeloma (RRMM)

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 215 publications

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives.

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives.

Journal: European journal of haematology

Published: January 19, 2026

Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.

Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.

Journal: Current oncology (Toronto, Ont.)

Published: January 10, 2026

Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.

Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.

Journal: Annals of hematology

Published: December 17, 2025

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma

Published: December 02, 2025

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Journal: Blood cancer journal

Published: October 13, 2025

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple Myeloma.

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple Myeloma.

Journal: Blood cancer discovery

Published: September 30, 2025

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Journal: Future oncology (London, England)

Published: September 15, 2025

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Journal: Blood cancer journal

Published: September 08, 2025

Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial.

Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 08, 2025

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

Journal: Blood reviews

Published: July 25, 2025

Chimeric antigen receptor T-cell therapy for multiple myeloma.

Chimeric antigen receptor T-cell therapy for multiple myeloma.

Journal: Current opinion in oncology

Published: July 17, 2025

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 06, 2025

Showing 1-12 of 215

Last Updated: 04/28/2026